![Bernard Coupal](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernard Coupal
Director/Board Member at CARDIAnove, Inc.
Bernard Coupal active positions
Companies | Position | Start | End |
---|---|---|---|
CARDIAnove, Inc.
![]() CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | Director/Board Member | - | - |
Career history of Bernard Coupal
Former positions of Bernard Coupal
Companies | Position | Start | End |
---|---|---|---|
Ambrilia Biopharma, Inc.
![]() Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Director/Board Member | 1998-12-31 | 2007-01-29 |
Procyon Biopharma, Inc.
![]() Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | Director/Board Member | - | 2006-03-02 |
Société Innovatech du Grand Montréal | President | 1991-12-31 | 1996-12-30 |
PainCeptor Pharma Corp.
![]() PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Director/Board Member | - | - |
Transfer Technologies Commercialisation Capital
![]() Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Chief Investment Officer | 1996-12-31 | - |
Private Equity Investor | 1996-12-31 | - | |
President | 1996-12-31 | - |
Training of Bernard Coupal
University of Florida | Doctorate Degree |
Ecole Polytechnique | Undergraduate Degree |
Statistics
International
Canada | 7 |
United States | 2 |
France | 2 |
Operational
Director/Board Member | 4 |
President | 2 |
Chief Investment Officer | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 6 |
---|---|
Procyon Biopharma, Inc.
![]() Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | Commercial Services |
PainCeptor Pharma Corp.
![]() PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
Transfer Technologies Commercialisation Capital
![]() Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
Société Innovatech du Grand Montréal | |
Ambrilia Biopharma, Inc.
![]() Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
CARDIAnove, Inc.
![]() CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | Health Technology |
- Stock Market
- Insiders
- Bernard Coupal
- Experience